About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RAS Quantification in Patients With Aliskiren or Candesartan

NCT01827202·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Medical University of Vienna

Age

18–99

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Chronic kidney disease stages III-IV (defined by modification of diet in renal disease (MDRD) formula)
Urinary albumin to creatinine ratio (UACR) \>300mg/g, UACR \>200mg/g if already receiving RAS blockade
Arterial hypertension

You may not be if

Age \<18 years
Diabetes mellitus type 2 (defined by WHO criteria)
Chronic kidney disease stage V (end-stage renal disease)
UACR \>3500mg/g
Severe hypertension (systolic blood pressure \>180mmHg)
Pregnancy

The record

StatusCompleted

PhasePhase 4

Taking part24

StartedDec 2012

UpdatedMar 16, 2016

Conditions

Hypertension Chronic Kidney Disease Proteinuria

Where1

Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis
Vienna, State of Vienna, Austria

Clareo Health | RAS Quantification in Patients With Aliskiren or Candesartan